Safety, Feasibility, and Effects of Time-Restricted Eating in Early-Stage Huntington’s Disease: Preliminary Analysis of a Clinical Pilot Trial
Objective: Evaluate whether 12 weeks of daily time-restricted eating (TRE) appears safe and feasible in persons with early-stage Huntington's disease (HD) and explore its effects…Comparative Efficacy and Safety of VMAT2 Inhibitors for Chorea in Huntington’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety and efficacy of vesicular monoamine transporter 2 (VMAT2) inhibitors (deutetrabenazine, tetrabenazine, valbenazine) in managing chorea in Huntington’s Disease (HD). Background:…Adult-Onset Post-Pump Chorea: A Rare Manifestation Post-Cardiac Surgery in a Puerto Rican Patient
Objective: To report the first case of adult-onset post-pump chorea in Puerto Rico and raise awareness of our patient’s atypical age and onset of clinical…Unraveling NKX2-1-related disorders: clinical, genetic, and neuroimaging insights from a global cohort
Objective: To analyze the clinical spectrum, genotype-phenotype correlations, and prognostic factors in NKX2-1-related disorders (NKX2-1-RD) through a multicenter study, providing insights for improved diagnosis and…Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders
Objective: We review the real-world prescribing practices and patient experiences with VMAT2 inhibitors in children. Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors are often prescribed…Developing a Framework for Huntington’s Disease Care Partner Training and Support – HD Care Partner Bootcamp Series
Objective: In this protocol we present a novel collaborative framework for a Huntington’s Disease (HD) Care Partner (CP) bootcamp series designed to train and support…A mindfulness-based intervention course in pre-manifest Huntington’s disease: analysis of pilot data
Objective: To assess feasibility and initial outcomes of a mindfulness-based intervention course in patients with pre-manifest, genetically confirmed Huntington’s disease (HD). Background: Mindfulness-based intervention courses…Patient Experience and Satisfaction With Once-Daily Deutetrabenazine Extended-Release Tablets for Treatment of Huntington Disease-Related Chorea
Objective: Objectives of this study were to explore patient-reported ease of use, effectiveness, and satisfaction during real-world use of once-daily (QD) deutetrabenazine extended-release tablets in…Valbenazine Improves Chorea Across Multiple Body Regions in Adults With Huntington’s Disease
Objective: To evaluate valbenazine’s effects on chorea across body regions in adults with Huntington’s disease (HD) using data from KINECT®-HD (NCT04102579). Background: Once-daily valbenazine is…Decreased Disease Burden in Motor-Related HD-HI Domains Among Adults With Huntington’s Disease Treated With Valbenazine
Objective: To evaluate the effects of valbenazine (VBZ) on mobility, abnormal movements, and hand/arm function as assessed using the Huntington’s Disease Health Index (HD-HI). Background:…
- 1
- 2
- 3
- …
- 11
- Next Page »